Cohance Lifesciences Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Operating Revenue	10,789	11,976	10,514	13,403	13,202	10,097
Other Revenue	-212.3	-	-	-	-	-0
Revenue	10,577	11,976	10,514	13,403	13,202	10,097
Revenue Growth (YoY)	0.88%	13.91%	-21.56%	1.52%	30.75%	21.10%
Cost of Revenue	3,074	3,757	3,716	5,882	5,741	4,372
Gross Profit	7,503	8,219	6,797	7,521	7,461	5,725
Selling, General & Admin	3,257	2,562	1,396	1,218	1,024	784.18
Research & Development	-	-	-	-	103.55	110.58
Other Operating Expenses	2,798	1,601	1,311	561.82	526.62	415.35
Operating Expenses	7,064	4,938	3,253	2,259	2,045	1,626
Operating Income	438.5	3,281	3,544	5,262	5,416	4,099
Interest Expense	-97.9	-123.5	-74.5	-128.11	-62.31	-91.44
Interest & Investment Income	12.7	12.7	19.3	58.32	0.69	2.68
Earnings From Equity Investments	-	-	-	-	411.12	537.36
Currency Exchange Gain (Loss)	116.6	116.6	81.2	214.38	164.21	95.59
Other Non Operating Income (Expenses)	12.4	12.4	66.8	32.9	0.02	0
EBT Excluding Unusual Items	482.3	3,299	3,637	5,439	5,930	4,643
Merger & Restructuring Charges	-302.6	-302.6	-31.1	-	-	-
Gain (Loss) on Sale of Investments	409.6	409.6	449.1	156.87	636.14	33.28
Gain (Loss) on Sale of Assets	-1.1	-1.1	-0.7	-0.07	106.03	0.34
Other Unusual Items	-95.3	34.3	2.7	1.17	3.73	-
Pretax Income	492.9	3,439	4,057	5,597	6,676	4,677
Income Tax Expense	98	791.5	1,054	1,484	2,138	1,053
Earnings From Continuing Operations	394.9	2,648	3,003	4,113	4,538	3,623
Minority Interest in Earnings	211.5	31	-	-	-	-
Net Income	606.4	2,679	3,003	4,113	4,538	3,623
Net Income to Common	606.4	2,679	3,003	4,113	4,538	3,623
Net Income Growth	-78.28%	-10.79%	-26.99%	-9.37%	25.24%	14.30%
Shares Outstanding (Basic)	255	255	255	255	255	255
Shares Outstanding (Diluted)	255	256	255	255	255	255
Shares Change (YoY)	-0.07%	0.49%	-	-	-	-
EPS (Basic)	2.38	10.52	11.80	16.16	17.83	14.23
EPS (Diluted)	2.35	10.45	11.80	16.16	17.83	14.23
EPS Growth	-78.51%	-11.45%	-26.99%	-9.37%	25.27%	14.30%
Free Cash Flow	-	1,325	3,329	1,713	2,548	2,717
Free Cash Flow Per Share	-	5.18	13.08	6.73	10.01	10.67
Dividend Per Share	-	-	-	3.000	2.000	2.000
Dividend Growth	-	-	-	50.00%	-	60.00%
Gross Margin	70.93%	68.63%	64.65%	56.11%	56.51%	56.70%
Operating Margin	4.15%	27.40%	33.71%	39.26%	41.02%	40.59%
Profit Margin	5.73%	22.37%	28.56%	30.69%	34.37%	35.88%
Free Cash Flow Margin	-	11.06%	31.66%	12.78%	19.30%	26.91%
EBITDA	1,385	4,056	4,090	5,726	5,795	4,407
EBITDA Margin	13.10%	33.87%	38.90%	42.72%	43.89%	43.65%
D&A For EBITDA	946.58	774.9	546	464.6	378.64	308.36
EBIT	438.5	3,281	3,544	5,262	5,416	4,099
EBIT Margin	4.15%	27.40%	33.71%	39.26%	41.02%	40.59%
Effective Tax Rate	19.88%	23.01%	25.98%	26.52%	32.02%	22.52%
Revenue as Reported	11,163	12,561	11,133	13,867	14,126	10,240
Advertising Expenses	-	57.2	34.8	34.89	18.83	18.37

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.